The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Plethora Gets European Marketing Approval For Ejaculation Treatment

Tue, 19th Nov 2013 10:49

LONDON (Alliance News) - Plethora Solutions Holdings PLC Tuesday said it has got marketing approval for its premature ejaculation treatment from the European Commission, a key step in its long-lasting efforts to commercialize the treatment.

The pharmaceutical company was founded in 2004 to develop the treatment, known as PSD502 or Prilocaine Lidocaine Plethora. Two years ago, it won back the right to regulatory and commercial development of PSD502 in Europe and other territories from Japanese pharmaceutical company Shionogi & Co. Ltd and in August, it announced an agreement with Shionogi's U.S. arm, Shionogi Inc., to pursue the regulatory approval for PSD502 globally.

It expects to file for marketing approval from the US Food and Drug Administration early in the New Year.

Its hopes rest on the success of the treatment. It currently has no other revenue streams.

Plethora Solutions shares were up 4.1% at 17.30 pence Tuesday morning.

By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
19 Nov 2013 08:07

AIM IN BRIEF: Centamin Further Reduces Stake In Nyota Minerals

Read more
30 Sep 2013 13:34

Plethora Cuts Losses As It Focuses Entirely Premature Ejaculation Treatment

Read more
23 Sep 2013 12:12

UK WINNERS & LOSERS: Ariana Resources Stands Out From Weak Gold Miners

Read more
20 Sep 2013 13:06

MARKET COMMENT: UK Trades Flat Prior To US Open; Nyota, Plethora Lead AIM

Read more
20 Sep 2013 12:43

Plethora Solutions Premature Ejaculation Spray Gets Positive Opinion

Read more
20 Sep 2013 12:26

UPDATE 1-New Roche breast cancer drug wins backing in Europe and Japan

* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g

Read more
12 Apr 2013 11:50

Plethora Solutions Chairman resigns

Plethora Solutions Holdings Chairman Bill Robinson is stepping down from his role at the pharmaceuticals company. Jim Mellon will take over as Chairman with immediate effect temporarily until a successor is found. Robinson, who has been Chairman since 2009, will remain a Non-Executive Director of

Read more
18 Mar 2013 14:25

Plethora Solutions secures much needed financing

Plethora Solutions has secured 2.1m pounds in funding after its subsidiary The Urology Co. fell into administration. The funds were raised through the placing of 106.2m new ordinary shares at a price of 2.0p per share, representing an 8.0% interest. It comes after the company announced it was in

Read more
14 Feb 2013 08:24

Plethora Solutions shares jump following new equity update

Shares in pharmaceuticals company Plethora Solutions jumped sharply on Thursday after the group reported that it was in 'advanced discussions' with an investor to provide new equity financing to the group. The group, whose share price had recently been declining, added that support was also being s

Read more
5 Feb 2013 11:07

Plethora Solutions shares plunge on urgent financing talks

Plethora Solutions is in urgent discussions with third parties to finance the company's working capital purposes. Shares in the pharmaceutical company plummeted 55.00% to 2.25p at 11:18 following Tuesday's announcement. The company said it remained focused on the development of SD502, a drug for

Read more
17 Oct 2012 15:15

Plethora's PSD502 drug has mass market potential

Plethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler. Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two

Read more
15 Mar 2012 12:06

Small caps round-up: HMV, Corero, ANGLE ...

HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in

Read more
14 Mar 2011 17:36

Plethora's testosterone boost

AIM-quoted sexual health products developer and distributor Plethora Solutions has added the pan-European rights for testosterone replacement treatment Striant SR to the UK rights it already has. Plethora has secured the rights from Columbia Laboratories and it will sell the product through its di

Read more
7 Sep 2010 13:48

Small caps round-up: Charlemagne, Highams, Hydro...

Hedge fund manager Charlemagne's assets under management rise have picked up in the past two months to stand at $3.04bn at end August. The modest recovery follows a fall in the first half to $2.8bn, blamed on declining markets. Operating profits were $1.2m, down from $1.3m, with one-off performanc

Read more
19 Jul 2010 07:25

Plethora Solutions Launches New Product, hi-Argenol >PLE.LN

LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), a U.K.-based specialty pharmaceutical company, said Monday it has launched a new product, hi-Argenol, for the maintenance and improvement of male sexual health. -Shares closed Friday at 11.75 pence valuing the company at GBP5.21 milli

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.